| 37.85 -4.54 (-10.71%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.43 | 1-year : | 61.24 |
| Resists | First : | 44.88 | Second : | 52.43 |
| Pivot price | 36.34  |
|||
| Supports | First : | 33.91 |
Second : | 27.13 |
| MAs | MA(5) : | 41 |
MA(20) : | 35.08 |
| MA(100) : | 23.84 |
MA(250) : | 16.09 |
|
| MACD | MACD : | 3 |
Signal : | 2.6 |
| %K %D | K(14,3) : | 73.9 |
D(3) : | 79.6 |
| RSI | RSI(14): 55.4 |
|||
| 52-week | High : | 44.88 | Low : | 4.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MBX ] has closed below upper band by 42.7%. Bollinger Bands are 106.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 42.66 - 42.87 | 42.87 - 43.04 |
| Low: | 36.57 - 36.83 | 36.83 - 37.03 |
| Close: | 37.49 - 37.88 | 37.88 - 38.2 |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Fri, 23 Jan 2026
MBX SEC Filings - MBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Mon, 08 Dec 2025
Certain Common Stock of MBX Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Mon, 17 Nov 2025
Mbx Biosciences stock hits 52-week high at 26.5 USD - Investing.com
Thu, 06 Nov 2025
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Wed, 29 Oct 2025
Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet - Yahoo Finance
Tue, 21 Oct 2025
Top Executive Makes Major Move with MBX Biosciences Stock! - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 107.1 (%) |
| Shares Short | 3,840 (K) |
| Shares Short P.Month | 4,100 (K) |
| EPS | 7.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | -24.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | 4.93 |
| PEG Ratio | 0 |
| Price to Book value | 4.36 |
| Price to Sales | 0 |
| Price to Cash Flow | -21.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|